منابع مشابه
Low-dose colchicine for secondary prevention of cardiovascular disease.
OBJECTIVES The objective of this study was to determine whether colchicine 0.5 mg/day can reduce the risk of cardiovascular events in patients with clinically stable coronary disease. BACKGROUND The presence of activated neutrophils in culprit atherosclerotic plaques of patients with unstable coronary disease raises the possibility that inhibition of neutrophil function with colchicine may re...
متن کاملLow-dose anticoagulation for secondary prevention in acute coronary syndrome.
After acute coronary syndrome (ACS), long-term dual antiplatelet therapy with acetylsalicylic acid and a P2Y(12) platelet receptor antagonist is the standard of care for secondary prevention. Despite the introduction of more potent P2Y(12) receptor antagonists, the risk of a recurrent vascular event within 12 months remains at approximately 10%, indicating a need for improved secondary preventi...
متن کاملStatins for Secondary Prevention of Cardiovascular Disease: The Right Dose
Since the publication of the 4S trial in 1994, there has emerged a consensus that statins save lives and decrease myocardial infarctions and strokes in coronary artery disease (CAD) patients irrespective of baseline serum cholesterol. However, there is controversy over the correct dose and the utility of the treatment-to-goal (cholesterol, low-density lipoprotein) approach. To answer remaining ...
متن کاملStatins for secondary prevention of cardiovascular disease: the right dose.
Since the publication of the 4S trial in 1994, there has emerged a consensus that statins save lives and decrease myocardial infarctions and strokes in coronary artery disease (CAD) patients irrespective of baseline serum cholesterol. However, there is controversy over the correct dose and the utility of the treatment-to-goal (cholesterol, low-density lipoprotein) approach. To answer remaining ...
متن کاملStatins for Secondary Prevention of Cardiovascular Disease: The Right Dose
Since the publication of the 4S trial in 1994, there has emerged a consensus that statins save lives and decrease myocardial infarctions and strokes in coronary artery disease (CAD) patients irrespective of baseline serum cholesterol. However, there is controversy over the correct dose and the utility of the treatment-to-goal (cholesterol, low-density lipoprotein) approach. To answer remaining ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Cardiology
سال: 2017
ISSN: 1759-5002,1759-5010
DOI: 10.1038/nrcardio.2017.175